A Practical Immunohistochemistry-Based Model for Predicting Pathologic Complete Response in Estrogen Receptor-Strong Positive and HER2-Negative Breast Cancer.

A clear trend of increasing pCR was observed as follows: 4.1% (score 0), 9.3% (score 1), 10.7% (score 2), 20.7% (score 3), and 47.5% (score 4) ( Supplementary Figure 3 ).

also in 19,460 other papers

Although the pCR group tended to have more early-stage tumors (cT1–T2, cN0–N1) and a high nuclear grade, these differences did not reach statistical significance.

also in 111,027 other papers